SCHEMBL1368038

SCHEMBL1368038

Cc1c(-c2ccc(NCCN3CCOCC3)nc2)cnc2c1N(Cc1c(F)ccc(F)c1Cl)CCN2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.45
PRKD3 O94806 2/20 0.45
SRC P12931 2/20 0.45
PLK4 O00444 1/20 0.45
JAK2 O60674 1/20 0.45
MAP4K4 O95819 1/20 0.45
ABL1 P00519 1/20 0.45
LCK P06239 1/20 0.45
CSF1R P07333 1/20 0.45
RET P07949 1/20 0.45
MET P08581 1/20 0.45
ROS1 P08922 1/20 0.45
FGFR1 P11362 1/20 0.45
FER P16591 1/20 0.45
FGFR3 P22607 1/20 0.45
LTK P29376 1/20 0.45
FLT4 P35916 1/20 0.45
FLT3 P36888 1/20 0.45
FRK P42685 1/20 0.45
PTK2 Q05397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13354615 0.92 ALK (0.46) CLK4PRKD3SRCPLK4JAK2
SCHEMBL12147224 0.83 JAK2 (0.43) CLK4PRKD3SRCPLK4JAK2
SCHEMBL12146408 0.78 ALK (0.61) CLK4PRKD3SRCPLK4JAK2
SCHEMBL1369192 0.78 JAK2 (0.46) CLK4PRKD3SRCPLK4JAK2
SCHEMBL1369125 0.76 ALK (0.51) CLK4PRKD3SRCPLK4JAK2
SCHEMBL12146467 0.74 ALK (0.51) CLK4PRKD3SRCPLK4JAK2
SCHEMBL16131181 0.73 JAK2 (0.41) CLK4PRKD3SRCPLK4JAK2
SCHEMBL1365989 0.72 ALK (0.50) CLK4PRKD3SRCPLK4JAK2
SCHEMBL1368989 0.71 HPGDS (0.49) ALDH1A1HPGD
SCHEMBL1368537 0.70 MAP4K3 (0.46) CLK4PRKD3SRCPLK4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365809-B1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMA INC (US) 2018-07-18 EP disclosed
EP-2365809-B1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMA INC (US) 2018-07-18 EP disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 US disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 CLK4 698/4885PRKD3 130/4885SRC 242/4885
US-20110288078-A1 PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS MAP3K5, MAP3K15, MAP4K2 CLK4 698/4885PRKD3 130/4885SRC 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.